Company news

Arrowhead Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ARWR: REDEMPLO® Approved by FDA for the Treatment of FCS…

November 19, 2025

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

November 17, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

November 5, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

November 3, 2025

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

October 20, 2025

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

October 6, 2025

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

September 10, 2025

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

September 9, 2025

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

September 1, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

August 26, 2025

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

August 12, 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

August 6, 2025

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

July 31, 2025

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

July 27, 2025

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

July 22, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

July 20, 2025

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

July 7, 2025

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

June 22, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

June 1, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 28, 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 11, 2025

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

May 6, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

April 29, 2025

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

April 14, 2025

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

March 9, 2025

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

March 5, 2025

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

February 27, 2025

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

February 24, 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

February 9, 2025

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

February 9, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

January 21, 2025

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

January 16, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

December 22, 2024

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

December 10, 2024

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

December 2, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

December 1, 2024

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

November 25, 2024

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

November 25, 2024

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

November 17, 2024

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

November 17, 2024

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

November 4, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

November 3, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

October 31, 2024

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

September 22, 2024

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

September 9, 2024

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

September 1, 2024

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

August 20, 2024

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

August 13, 2024

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

August 7, 2024

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

August 7, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.